$AMIX
Autonomix Medical, Inc. Stock $amix

$amix Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000143774924018932 Filed on May 31, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2024
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.799M	$1.575M	$5.249M
YoY Change		365.63%	293.68%
% of Gross Profit
Research & Development	$954.0K	$841.0K	$2.225M
YoY Change	159.24%	163.45%	198.66%
% of Gross Profit
Depreciation & Amortization	$43.00K	$46.00K	$81.00K
YoY Change
% of Gross Profit
Operating Expenses	$2.753M	$2.416M	$12.03M
YoY Change	216.07%	267.46%	504.52%
Operating Profit	-$2.753M		-$12.03M
YoY Change	216.07%		504.52%
Interest Expense	$54.00K	$34.00K	$48.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$54.00K	-$3.026M	-$3.396M
YoY Change	800.0%
Pretax Income	-$2.699M	-$5.408M	-$15.43M
YoY Change	212.02%	722.53%	675.18%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$2.700M	-$5.408M	-$15.40M
YoY Change	212.14%	722.53%	670.0%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.14		-$1.05
Diluted Earnings Per Share	-$0.14	-$0.29	-$0.82
COMMON SHARES
Basic Shares Outstanding	18.85M	18.79M shares	14.63M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2024 Q1	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.751M	$8.608M	$8.608M
YoY Change			895.6%
Cash & Equivalents	$6.800M	$8.608M
Short-Term Investments
Other Short-Term Assets	$325.0K	$783.0K	$783.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$7.076M	$9.391M	$9.391M
YoY Change		985.66%	986.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.00K	$16.00K	$16.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$19.00K	$16.00K	$16.00K
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$7.076M	$9.391M	$9.391M
Total Long-Term Assets	$19.00K	$16.00K	$16.00K
Total Assets	$7.095M	$9.407M	$9.407M
YoY Change		987.51%	988.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$287.0K	$492.0K	$492.0K
YoY Change		184.39%	185.22%
Accrued Expenses	$476.0K	$285.0K	$285.0K
YoY Change		493.75%	492.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$763.0K	$777.0K	$777.0K
YoY Change		251.58%	252.22%
LONG-TERM LIABILITIES
Long-Term Debt	$1.043M	$1.002M	$1.002M
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$1.043M	$1.002M	$1.002M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$763.0K	$777.0K	$777.0K
Total Long-Term Liabilities	$1.043M	$1.002M	$1.002M
Total Liabilities	$1.806M	$1.779M	$1.779M
YoY Change		704.98%	706.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$41.70M	-$39.00M
YoY Change		65.65%
Common Stock	$19.00K	$19.00K
YoY Change		58.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.289M	$7.628M	$7.628M
YoY Change
Total Liabilities & Shareholders Equity	$7.095M	$9.407M	$9.407M
YoY Change		987.51%	988.02%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2024
OPERATING ACTIVITIES
Net Income	-$2.700M	-$5.408M	-$15.40M
YoY Change	212.14%	722.53%	670.0%
Depreciation, Depletion And Amortization	$43.00K	$46.00K	$81.00K
YoY Change
Cash From Operating Activities	-$1.900M	-$2.287M	-$6.600M
YoY Change	171.43%	93.03%	247.37%
INVESTING ACTIVITIES
Capital Expenditures	$5.000K	$3.000K	$19.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$5.000K	-$3.000K	-$19.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$2.840M
YoY Change			320.74%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	9.680M	$14.41M
YoY Change	-100.0%	1334.07%	2034.81%
NET CHANGE
Cash From Operating Activities	-$1.900M	-2.287M	-$6.600M
Cash From Investing Activities	-$5.000K	-3.000K	-$19.00K
Cash From Financing Activities	$0.00	9.680M	$14.41M
Net Change In Cash	-$1.857M	7.390M	$7.743M
YoY Change	-189.54%	-1549.59%	-756.74%
FREE CASH FLOW
Cash From Operating Activities	-$1.900M	-$2.287M	-$6.600M
Capital Expenditures	$5.000K	$3.000K	$19.00K
Free Cash Flow	-$1.905M	-$2.290M	-$6.619M
YoY Change	172.14%		248.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7100000
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18846094
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18846094
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12336571
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12336571
CY2023	us-gaap	Revenues Revenues	0	usd
CY2023Q1	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2024	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2024	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	usd
CY2024	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	amix	Reserve For Uncertain Tax Positions ReserveForUncertainTaxPositions	0	usd
CY2024	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-41940
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1607810
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	21 Waterway Avenue, Suite 300
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	The Woodlands
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77380
CY2024	dei	City Area Code CityAreaCode	713
CY2024	dei	Local Phone Number LocalPhoneNumber	588-6150
CY2024	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2024	dei	Trading Symbol TradingSymbol	AMIX
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2024	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18845044
CY2024	dei	Auditor Name AuditorName	FORVIS, LLP
CY2024	dei	Auditor Location AuditorLocation	Atlanta, Georgia
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8608000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	865000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	783000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	0	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	9391000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	865000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	16000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	0	usd
CY2024Q1	us-gaap	Assets Assets	9407000	usd
CY2023Q1	us-gaap	Assets Assets	865000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	492000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	173000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	285000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	48000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	777000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	221000	usd
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1002000	usd
CY2023Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1002000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	usd
CY2024Q1	us-gaap	Liabilities Liabilities	1779000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	221000	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	19000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	46578000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24175000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38969000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23543000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	7628000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	644000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9407000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	865000	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5249000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1245000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2225000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	745000	usd
CY2024	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-4556000	usd
CY2023	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-0	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	12030000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1990000	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-12030000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1990000	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3444000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-0	usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	79000	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	-0	usd
CY2024	us-gaap	Investment Income Interest InvestmentIncomeInterest	127000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3396000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15426000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1990000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15426000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1990000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14626282
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12023112
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1959000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1990000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	675000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	644000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15426000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	618000	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2840000	usd
CY2024	amix	Stock Issued During Period Value Initial Public Offering StockIssuedDuringPeriodValueInitialPublicOffering	9875000	usd
CY2024	amix	Stock Issued During Period Value Extinguishment Of Convertible Debt StockIssuedDuringPeriodValueExtinguishmentOfConvertibleDebt	500000	usd
CY2024	amix	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	0	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	577000	usd
CY2024	amix	Warrants Issued Fair Value Issued For Termination Agreement WarrantsIssuedFairValueIssuedForTerminationAgreement	8000000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	7628000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15426000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1990000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	618000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	81000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	usd
CY2024	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-4556000	usd
CY2023	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-0	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3444000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2024	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	478000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-9000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	320000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	81000	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	237000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	46000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6648000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1854000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2840000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	675000	usd
CY2024	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2000000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2024	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	10866000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2024	amix	Payments For Initial Public Offering Issuance Costs PaymentsForInitialPublicOfferingIssuanceCosts	1296000	usd
CY2023	amix	Payments For Initial Public Offering Issuance Costs PaymentsForInitialPublicOfferingIssuanceCosts	-0	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14410000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	675000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7743000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1179000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	865000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2044000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8608000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	865000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	577000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	usd
CY2024	us-gaap	Stock Issued1 StockIssued1	2000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2024	amix	Class Of Warrant Or Right Fair Value Issued For Issuance Costs From Ipo ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo	225000	usd
CY2023	amix	Class Of Warrant Or Right Fair Value Issued For Issuance Costs From Ipo ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo	0	usd
CY2024	amix	Ipo Proceeds Holdback Provision IpoProceedsHoldbackProvision	305000	usd
CY2023	amix	Ipo Proceeds Holdback Provision IpoProceedsHoldbackProvision	0	usd
CY2024	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	670
CY2023	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	0
CY2024	amix	Debt Conversion Debt Issuance Costs Converted Common Shares DebtConversionDebtIssuanceCostsConvertedCommonShares	-170000	usd
CY2023	amix	Debt Conversion Debt Issuance Costs Converted Common Shares DebtConversionDebtIssuanceCostsConvertedCommonShares	0	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15400000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2000000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6600000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1900000	usd
CY2024	us-gaap	Revenues Revenues	0	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39000000	usd
CY2024Q1	amix	Working Capital Deficit WorkingCapitalDeficit	8600000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Use of Estimates in Financial Statement Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The preparation of these financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include the valuation of equity related instruments, and initial and recurring fair value measurements for the warrant liability. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024	amix	Payments For Initial Public Offering Issuance Costs PaymentsForInitialPublicOfferingIssuanceCosts	1300000	usd
CY2024Q1	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8913169
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6569929
CY2024	us-gaap	Advertising Expense AdvertisingExpense	1700000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	100000	usd
CY2024	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"><i>Reclassifications</i></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had <em style="font: inherit;">no</em> effect on the reported results of operations.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Correction of an Immaterial Error in the Prior Period Financial Statements</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2024</em> (<em style="font: inherit;"> March 31, 2024), </em>the Company determined that the prior year financial statements had an error caused by an immaterial classification error of certain research and development expense in accordance with ASC <em style="font: inherit;">730.</em> As a result, certain prior year amounts have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with <i>SEC Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99</em></i>, “<i>Materiality</i>,” (<i>ASC Topic <em style="font: inherit;">250,</em> Accounting Changes and Error Corrections</i>). Based on this assessment, the Company concluded that these classification error corrections in its Statements of Operations are <em style="font: inherit;">not</em> material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had <em style="font: inherit;">no</em> impact on the fiscal year <em style="font: inherit;">2023</em> Balance Sheet, Statements of Cash Flows, or Statement of Changes in Stockholders’ Equity. Further, the immaterial corrections did <em style="font: inherit;">not</em> result in a change in operating losses, net loss, or basic or diluted earnings per share in the Income Statement. Accordingly, the Company corrected the previously reported immaterial errors for the year ended <em style="font: inherit;"> March 31, 2023 </em>in this Annual Report on Form <em style="font: inherit;">10</em>-K.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"><span style="background-color:#ffffff;">A summary of immaterial corrections reflecting the prior period impact to the Company’s Statement of Operations, for the year ended <em style="font: inherit;"> March 31, 2023 </em>is shown below (in thousands):</span></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="font-size: 10pt; width: 100%; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="text-align: center; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="text-align: center; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: "Times New Roman", Times, serif;"><em style="font: inherit;">As Revised</em></p> </td><td style="font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: "Times New Roman", Times, serif;"><em style="font: inherit;">March 31, 2023</em></p> </td><td style="font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: "Times New Roman", Times, serif;"><em style="font: inherit;">Correction</em></p> </td><td style="font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom-style: solid; border-bottom-color: rgb(0, 0, 0);"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: "Times New Roman", Times, serif;"><em style="font: inherit;">March 31, 2023</em></p> </td><td style="font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt; width: 55%;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: "Times New Roman", Times, serif;">General and administrative expense</p> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,333</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">(88</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt;">1,245</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: "Times New Roman", Times, serif;">Research and development expense</p> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">657</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">88</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">745</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-size: 10pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; font-family: "Times New Roman", Times, serif;">Net Loss</p> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,990</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,990</td><td style="width: 1%; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-4600000	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2023Q1	amix	Class Of Warrant Or Right Outstanding Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice	0
CY2023Q1	amix	Class Of Warrant Or Right Aggregate Intrinsic Value Outstanding ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding	0	usd
CY2024	amix	Class Of Warrant Or Right Grants In Period ClassOfWarrantOrRightGrantsInPeriod	500000
CY2024	amix	Class Of Warrant Or Right Grants In Period Weighted Average Exercise ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise	1
CY2024	amix	Class Of Warrant Or Right Exercises In Period ClassOfWarrantOrRightExercisesInPeriod	-0
CY2024	amix	Class Of Warrant Or Right Exercises In Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice	0
CY2024	amix	Class Of Warrant Or Right Forfeitures In Period ClassOfWarrantOrRightForfeituresInPeriod	-0
CY2024	amix	Class Of Warrant Or Right Forfeitures In Period Weighted Average Exercise Price ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024	amix	Class Of Warrant Or Right Expirations In Period ClassOfWarrantOrRightExpirationsInPeriod	-0
CY2024	amix	Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	500000
CY2024Q1	amix	Class Of Warrant Or Right Outstanding Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice	1
CY2024	amix	Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm	P4Y5M23D
CY2024Q1	amix	Class Of Warrant Or Right Aggregate Intrinsic Value Outstanding ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding	1010000	usd
CY2024Q1	amix	Class Of Warrant Or Right Exercisable Number ClassOfWarrantOrRightExercisableNumber	500000
CY2024	amix	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	1
CY2024	amix	Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm	P4Y5M23D
CY2024Q1	amix	Class Of Warrant Or Right Aggregate Intrinsic Value Exercisable ClassOfWarrantOrRightAggregateIntrinsicValueExercisable	1010000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	1996400
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	17072147	usd
CY2024Q1	amix	Sharebased Compensation Arrangement By Sharebased Payment Award Nonoption Equity Instruments Exercisable Number Outstanding Number SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber	5736236
CY2024Q1	amix	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice	0.08
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2003600
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.33
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-0
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	-0
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2003600
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.33
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y4M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1680672	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	239217
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y11M15D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	244001	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6569929
CY2023Q1	amix	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	0.02
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P5Y11M26D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	12982587	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	1679765
CY2024	amix	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice	0.25
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2485301
CY2024	amix	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice	0.03
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	19824
CY2024	amix	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Forfeitures In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.5
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	-0
CY2024	amix	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Expirations In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5744569
CY2024Q1	amix	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	0.08
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P4Y9M18D
CY2024	amix	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm	P4Y9M18D
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	17063647	usd
CY2024	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	800000	usd
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3239	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-418	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1697	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.1101	pure
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0	pure
CY2024	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-69	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.0045	pure
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0	pure
CY2024	amix	Effective Income Tax Rate Reconciliation Change In State Rate Amount EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount	-190	usd
CY2024	amix	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	0.0123	pure
CY2023	amix	Effective Income Tax Rate Reconciliation Change In State Rate Amount EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount	0	usd
CY2023	amix	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	0	pure
CY2024	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-192	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0124	pure
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1993	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1291	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	418	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.21	pure
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2024Q1	amix	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	602	usd
CY2023Q1	amix	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	124	usd
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2643	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1342	usd
CY2024Q1	amix	Deferred Tax Assets Cash Accrual DeferredTaxAssetsCashAccrual	72	usd
CY2023Q1	amix	Deferred Tax Assets Cash Accrual DeferredTaxAssetsCashAccrual	0	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	142	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	usd
CY2024Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3459	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1466	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3459	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1466	usd
CY2024Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2024Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2024Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	11200000	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1900000	usd
CY2024	dei	Auditor Name AuditorName	FORVIS, LLP
CY2024	dei	Auditor Firm AuditorFirmId	686
CY2024	dei	Auditor Location AuditorLocation	Atlanta, Georgia

Files In Submission

Name	View Source	Status
0001437749-24-018932-index-headers.html	Edgar Link	pending
0001437749-24-018932-index.html	Edgar Link	pending
0001437749-24-018932.txt	Edgar Link	pending
0001437749-24-018932-xbrl.zip	Edgar Link	pending
a01.jpg	Edgar Link	pending
a02.jpg	Edgar Link	pending
a03.jpg	Edgar Link	pending
a04a.jpg	Edgar Link	pending
a04b.jpg	Edgar Link	pending
a05.jpg	Edgar Link	pending
a06.jpg	Edgar Link	pending
a07.jpg	Edgar Link	pending
amix-20240331.xsd	Edgar Link	pending
amix.jpg	Edgar Link	pending
amix20240331_10k.htm	Edgar Link	pending
ex_681666.htm	Edgar Link	pending
ex_681781.htm	Edgar Link	pending
ex_681782.htm	Edgar Link	pending
ex_681783.htm	Edgar Link	pending
ex_681784.htm	Edgar Link	pending
ex_681785.htm	Edgar Link	pending
ex_681785img001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
amix20240331_10k_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
amix-20240331_lab.xml	Edgar Link	unprocessable
amix-20240331_cal.xml	Edgar Link	unprocessable
amix-20240331_def.xml	Edgar Link	unprocessable
amix-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMIX
Autonomix Medical, Inc. Stock $amix

2024 Q2 Form 10-K Financial Statement

#000143774924018932 Filed on May 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMIX Autonomix Medical, Inc. Stock $amix

2024 Q2 Form 10-K Financial Statement

#000143774924018932 Filed on May 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMIX
Autonomix Medical, Inc. Stock $amix